首页|期刊导航|Oncology Research|Neurotransmitter-Mediated Signaling in Glioblastoma and Glial Tumors:Biology and Therapeutic Opportunities

Neurotransmitter-Mediated Signaling in Glioblastoma and Glial Tumors:Biology and Therapeutic OpportunitiesOA

中文摘要

Glioblastoma(GB)is the most common primary malignant brain tumor of adulthood,and despite optimal safe resection and chemoradiation,it is still lethal.Neuroscience of cancer has shown that neuronal activities,as well as neurotransmitters,play an active role in the glioma microenvironment.This article aims to integrate the existing literature on the role of neurotransmitters and their receptors in glioblastoma,as well as other gliomas,highlighting areas of therapeutic intervention in the neuron-tumor interface.We will describe the neuro–glioma interface,including functional neuron–glioma synapses and activity-dependent tumor growth.We will also discuss major neurotransmitter systems involved in glioma pathobiology:glutamate,gamma aminobutyric acid,acetylcholine,dopamine,serotonin,norepinephrine,and other neurotransmitters.We will highlight that these neurotransmitter systems activate common intracellular signaling pathways that control tumor proliferation,invasion,metabolic reprogramming,immune suppression,therapy resistance,etc.In addition,some reports have found tumor-suppressing effects depending on the context.The involvement of neurotransmitter-driven signaling pathways represents a promising area of clinical potential in glioma pathobiology.In particular,focusing on key neurotransmitter systems with blood–brain barrier-permeable agents like alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid(AMPA/X_(c)^(−))system,Muscarinic acetylcholine receptor M3(CHRM3),dopamine receptor D2,monoamine oxidase A,etc.,may enhance drug-repurposing research as well as development of novel anti–neuron–glioma agents.

Pietro Tralongo;Mariagiovanna Ballato;Valeria Zuccalà;Vincenzo Fiorentino;Walter Giordano;Giovanna Casili;Fabiola Bellinghieri;Gerardo Caruso;Filippo Flavio Angileri;Guido Fadda;Maurizio Martini;Maria Caffo

Department of Biomedical,Dental,Morphological and Functional Imaging Sciences,University of Messina,Messina,ItalyDepartment of Biomedical,Dental,Morphological and Functional Imaging Sciences,University of Messina,Messina,ItalyDepartment of Human Pathology of Adults and Developmental Age“Gaetano Barresi”,Division of Pathology,University of Messina,Messina,ItalyDepartment of Human Pathology of Adults and Developmental Age“Gaetano Barresi”,Division of Pathology,University of Messina,Messina,ItalyDepartment of Biomedical,Dental,Morphological and Functional Imaging Sciences,University of Messina,Messina,ItalyDepartment of Chemical,Biological,Pharmaceutical and Environmental Sciences,University of Messina,Messina,ItalySchool of Medicine and Surgery,University of Roma Tor Vergata,Rome,ItalyDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging,Unit of Neurosurgery,University of Messina,Messina,ItalyDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging,Unit of Neurosurgery,University of Messina,Messina,ItalyDepartment of Human Pathology of Adults and Developmental Age“Gaetano Barresi”,Division of Pathology,University of Messina,Messina,ItalyDepartment of Human Pathology of Adults and Developmental Age“Gaetano Barresi”,Division of Pathology,University of Messina,Messina,ItalyDepartment of Biomedical and Dental Sciences and Morphofunctional Imaging,Unit of Neurosurgery,University of Messina,Messina,Italy

医药卫生

Glioblastomacancer neuroscienceneuron–glioma synapseneurotransmitter receptorsmonoaminesdrug repurposingneurotransmittersgliomasignaling

《Oncology Research》 2026 (6)

P.1-21,21

Funded by the European Union—Next Generation EU—NRPP M6C2—Investment 2.1 Enhancement and Strenghtening of Biomedical Research in the NHS(Cod.ID.PNRR-TR1-2023-12377972 CUP H43C24000520006).

10.32604/or.2026.076088

评论